Viking Therapeutics, Inc.
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
About
CEO
Dr. Brian Lian Ph.D.
Employees
30
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNCM
Address
9920 Pacific Heights Boulevard, San Diego, CA 92121, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Oct 21, 2025 | — | — | — | — |
| Jul 22, 2025 | — | — | — | — |
| Apr 22, 2025 | — | — | — | — |
| Feb 6, 2025 | -0.28 | — | — | — |
| Oct 24, 2024 | -0.25 | -0.22 | 0.03 | -12.00% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 4 | — | 11 |
| Average estimate | — | -0.28 | — | -1.42 |
| Low estimate | — | -0.29 | — | -2.04 |
| High estimate | — | -0.24 | — | -1.06 |
| Last year EPS | — | -0.26 | — | -0.96 |
[stock_revenue_estimate]
Growth estimates
Current qtr
-6.960%
Next qtr. (Mar 2025)
-5.770%
Current year
-5.620%
Next year (Dec 2025)
-47.290%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating expense | |||||
| Research & development | 63.81M | 54.23M | 44.98M | 31.93M | 23.56M |
| Selling general and admin | 37.02M | 16.12M | 10.70M | 10.73M | 9.13M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -100.83M | -70.36M | -55.68M | -42.66M | -32.69M |
| Non operating interest income | |||||
| Income | 15.02M | 1.59M | 703,000 | 3.23M | 7.05M |
| Expense | — | — | — | — | — |
| Other income expense | — | -42,000 | 7,000 | 40,000 | 4,000 |
| Pretax income | -85.90M | -68.87M | -54.99M | -39.50M | -25.78M |
| Tax provision | — | — | — | — | — |
| Net income | -85.90M | -68.87M | -54.99M | -39.50M | -25.78M |
| Basic EPS | -0.91 | -0.90 | -0.71 | -0.54 | -0.36 |
| Diluted EPS | -0.91 | -0.90 | -0.71 | -0.54 | -0.36 |
| Basic average shares | 94.35M | 76.83M | 77.20M | 72.60M | 71.96M |
| Diluted average shares | 94.35M | 76.83M | 77.20M | 72.60M | 71.96M |
| EBITDA | -100.54M | -70.02M | -55.39M | -42.43M | -32.43M |
| Net income from continuing op. | -85.90M | -68.87M | -54.99M | -39.50M | -25.78M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 368.49M | 168.53M | 210.66M | 256.50M | 284.26M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 55.52M | 36.63M | 26.37M | 29.12M | 8.38M |
| Other short term investments | 306.56M | 118.85M | 175.73M | 219.27M | 267.26M |
| Accounts receivable | — | — | — | — | — |
| Other receivables | — | — | — | — | — |
| Inventory | — | — | — | — | — |
| Prepaid assets | 2.62M | 8.14M | 7.81M | 7.72M | 7.86M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 2.52M | 3.41M | 619,000 | — | — |
| Non current assets | |||||
| Properties | — | — | — | — | 598,000 |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | — | — | — | — | — |
| Construction in progress | — | — | — | — | — |
| Leases | — | — | — | 321,000 | 598,000 |
| Accumulated depreciation | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 106,000 | 38,000 | 76,000 | 48,000 | 128,000 |
| Total liabilities | 20.07M | 23.21M | 8.78M | 12.16M | 7.14M |
| Current liabilities | |||||
| Accounts payable | 7.51M | 8.53M | 1.44M | 3.99M | 2.43M |
| Accrued expenses | 11.30M | 13.11M | 7.31M | 7.81M | 4.04M |
| Short term debt | 324,000 | 304,000 | 29,000 | 330,000 | 302,000 |
| Deferred revenue | — | — | — | — | — |
| Tax payable | — | — | — | — | — |
| Pensions | — | — | — | — | — |
| Other current liabilities | — | — | — | — | — |
| Non current liabilities | |||||
| Long term debt | 936,000 | 1.26M | — | 29,000 | 360,000 |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | — | — | — | — | — |
| Shareholders equity | |||||
| Common stock | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 |
| Retained earnings | -377.94M | -292.05M | -223.18M | -168.19M | -128.70M |
| Other shareholders equity | -389,000 | -1.10M | -549,000 | -54,000 | 12,000 |
| Total shareholders equity | 348.42M | 145.32M | 201.88M | 244.34M | 277.12M |
| Additional paid in capital | 733.55M | 445.27M | 425.61M | 412.59M | 405.80M |
| Treasury stock | 6.80M | 6.80M | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||
| Net Income | -85.90M | -68.87M | -54.99M | -39.50M | -25.78M | -22.06M | -20.58M | -14.73M | -23.40M | -21.88M | -146,247 |
| Depreciation | 292,000 | 291,000 | 296,000 | 277,000 | 260,000 | — | — | — | — | — | — |
| Deferred Taxes | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 16.75M | 8.67M | 6.10M | 5.82M | 3.74M | 2.61M | 1.45M | 1.79M | 2.60M | 6,258 | 3,554 |
| Other Non-Cash Items | 131,000 | 100,000 | 29,000 | 138,000 | 334,000 | -208,000 | 2.50M | 862,619 | 11.32M | -1.65M | 39,014 |
| Accounts Receivable | 321,000 | 614,000 | 1.18M | 2.59M | 1.97M | — | — | — | — | — | — |
| Accounts Payable | -1.02M | 7.09M | -2.54M | 1.56M | 1.47M | -508,000 | 264,000 | 677,185 | 219,237 | 190,296 | 20,062 |
| Other Assets & Liabilities | -347,000 | -189,000 | -342,000 | -333,000 | -269,000 | — | — | 40,659 | -79,225 | — | -775 |
| Operating Cash Flow | -69.77M | -52.29M | -50.28M | -29.45M | -18.27M | -20.17M | -16.36M | -11.36M | -9.34M | -23.34M | -84,392 |
| Investing Activities | |||||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — | — | — | — |
| Net Intangibles | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | — | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | -478.30M | -121.43M | -168.02M | -280.64M | -362.41M | -348.20M | -22.53M | -16.92M | -16.03M | — | — |
| Sale of Investments | 299.22M | 176.18M | 205.98M | 322.20M | 369.87M | 82.48M | 20.80M | 19.95M | 2.56M | — | — |
| Investing Cash Flow | -179.09M | 54.75M | 37.96M | 41.57M | 7.46M | -265.73M | -1.73M | 3.03M | -13.47M | — | — |
| Financing Activities | |||||||||||
| Long-Term Debt Issuance | — | — | — | — | — | — | — | — | — | 2.50M | 260,350 |
| Long-Term Debt Payments | — | — | — | — | — | -3.83M | -77,000 | -94,861 | — | — | — |
| Other Financing Charges | 264.61M | 10.11M | -753,000 | -322,000 | -224,000 | -892,000 | -522,000 | -1.13M | -3.20M | -332,337 | — |
| Financing Cash Flow | 264.61M | 3.32M | -753,000 | -322,000 | -224,000 | 291.88M | 21.75M | 10.33M | 22.19M | 2.17M | 257,854 |
| Other Cash Details | |||||||||||
| End Cash Position | 55.52M | 36.63M | 26.37M | 29.12M | 8.38M | 24.78M | 8.99M | 3.08M | 768,550 | 755,857 | 179,619 |
| Income Tax Paid | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | — | — | — | — | — | 81,000 | 123,000 | 205,139 | — | — | — |
| Free Cash Flow | -73.38M | -48.40M | -47.59M | -21.78M | -24.75M | -18.76M | -14.76M | -11.07M | -8.73M | -1.59M | -78,235 |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Fidelity Growth Company Fund | Nov 30, 2024 | 3,857,755 | 124.88M | 3.46% |
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 3,324,440 | 107.61M | 2.98% |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | Nov 30, 2024 | 2,770,369 | 89.68M | 2.49% |
| Vanguard Small-Cap Index Fund | Sep 30, 2024 | 2,634,893 | 85.29M | 2.36% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 1,657,428 | 53.65M | 1.49% |
| Vanguard Small-Cap Growth Index Fund | Sep 30, 2024 | 1,452,921 | 47.03M | 1.30% |
| Fidelity Growth Company K6 Fund | Nov 30, 2024 | 1,356,358 | 43.91M | 1.22% |
| Fidelity Series Growth Company Fund | Nov 30, 2024 | 1,166,800 | 37.77M | 1.05% |
| MFS Mid Cap Growth Fund | Nov 30, 2024 | 867,711 | 28.09M | 0.78% |
| Fidelity Advisor Biotechnology Fund | Nov 30, 2024 | 716,687 | 23.20M | 0.64% |
Article
2 Stocks to Buy With Less Than $40
Some think investing in stocks requires substantial start-up capital, but that's false. Even with a modest sum, like $40, investors can acquire shares of companies whose long-term prospects look exciting, and all for the price of a few breakfast items.
Feb 10, 2025
Article
3 No-Brainer Healthcare Stocks to Buy With $200 Right Now
Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative biotech that may launch game-changing products down the road.
Feb 10, 2025
Article
2 Stocks That Could Soar Again in 2025
Many companies in the biotech industry performed well last year. Two in particular stood out: Viking Therapeutics (VKTX 3.50%) and Summit Therapeutics (SMMT -2.71%).
Feb 8, 2025
